XVIVO Perfusion reports net sales of SEK 178,3 million for Q2 2025, a decrease of 15 percent (organic -11 percent) compared to the previous year, driven by lower EVLP activity and reduced heart sales. The Abdominal business area grew by 19 percent, while Thorax and Services declined. Adjusted EBITDA decreased to SEK 23,3 million (13 percent margin). The company received FDA approval for the DELIVER study and the PRESERVE CAP study, strengthening future growth prospects for heart and liver transplantation.
|
Published July 11, 2025
XVIVO reports negative growth for Q2
Notes
Galecto acquires Damora Therapeutics
Cereno Scientific submits protocol for Phase IIb study to FDA
Camurus shows promising results for monthly semaglutide depot
Lytix Biopharma presents new phase II data for ruxotemitide
Ascendis Pharma reports long-term positive results for the treatment of hypoparathyroidism
Xintela carries out rights issue of SEK 72,8 million
Sobi shows strong Phase III results for olezarsen in severe hypertriglyceridemia
NEWSLETTER
Upcoming events
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
